Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.78 |
| ▸ | NPC1 | O15118 | 1/20 | 0.78 |
| ▸ | POLB | P06746 | 1/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | HTT | P42858 | 1/20 | 0.69 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.67 |
| ▸ | GAA | P10253 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21098369 | 0.93 | SMN1; SMN2 (0.89) | SMN1; SMN2NPC1POLBALDH1A1MAPT | |
| SCHEMBL4484066 | 0.88 | SMN1; SMN2 (0.80) | SMN1; SMN2NPC1POLBALDH1A1MAPT | |
| SCHEMBL13211944 | 0.87 | SMN1; SMN2 (0.78) | SMN1; SMN2NPC1POLBALDH1A1MAPT | |
| SCHEMBL6571604 | 0.87 | SMN1; SMN2 (0.84) | SMN1; SMN2NPC1POLBALDH1A1MAPT | |
| SCHEMBL5257694 | 0.87 | SMN1; SMN2 (0.78) | SMN1; SMN2NPC1POLBALDH1A1MAPT | |
| SCHEMBL95881 | 0.87 | SMN1; SMN2 (0.78) | SMN1; SMN2NPC1POLBALDH1A1MAPT | |
| SCHEMBL16359671 | 0.87 | SMN1; SMN2 (0.78) | SMN1; SMN2NPC1POLBALDH1A1MAPT | |
| SCHEMBL1775216 | 0.86 | SMN1; SMN2 (0.82) | SMN1; SMN2NPC1POLBALDH1A1MAPT | |
| SCHEMBL16869708 | 0.85 | KMT2A (0.75) | SMN1; SMN2NPC1POLBKDM4EHTT | |
| SCHEMBL13766445 | 0.85 | SMN1; SMN2 (0.74) | SMN1; SMN2NPC1POLBALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4568687-A | THROMBOXANE SYNTHETASE TNZYME INHIBITORS; HYPOTENSIVE AGENTS, CARDIOTONIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1986-02-04 | — | — | US | claimed |
| EP-1423388-B1 | 2-ARYLAMINO-PYRIMIDINES FOR THE TREATMENT OF GSK3-RELATED DISORDERS | ASTRAZENECA AB (SE) | 2008-12-03 | — | — | EP | disclosed |
| US-7078410-B2 | 2-arylamino-pyrimidines for the treatment of GSK3-related disorders | ASTRAZENECA AB (SE) | 2006-07-18 | — | — | US | disclosed |
| US-6855719-B1 | Imidazo[1,2-A]pyridine and pyrazolo[2,3-A]pyridine derivatives | ASTRAZENECA AB (SE) | 2005-02-15 | — | — | US | disclosed |
| US-20040106574-A1 | 2-Arylamino-pyrimidines for the treatment of gsk3-related disorders | ASTRAZENECA AB (SE) | 2004-06-03 | — | — | US | disclosed |
| EP-1423388-A2 | 2-ARYLAMINO-PYRIMIDINES FOR THE TREATMENT OF GSK3-RELATED DISORDERS | AstraZeneca AB (SE) | 2004-06-02 | — | — | EP | disclosed |
| EP-1214318-B1 | IMIDAZO[1,2-A]PYRIDINE AND PYRAZOLO[2,3-A]PYRIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-10-08 | — | — | EP | disclosed |
| WO-2002066480-A2 | 2-ARYLAMINO-PYRIMIDINES FOR THE TREATMENT OF GSK3-RELATED DISORDERS | ASTRAZENECA AB (SE) | 2002-08-29 | — | — | WO | disclosed |
| EP-1214318-A1 | IMIDAZO[1,2-A]PYRIDINE AND PYRAZOLO[2,3-A]PYRIDINE DERIVATIVES | AstraZeneca AB (SE) | 2002-06-19 | — | — | EP | disclosed |
| WO-2001014375-A1 | IMIDAZO[1,2-A]PYRIDINE AND PYRAZOLO[2,3-A]PYRIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-03-01 | — | — | WO | disclosed |
| EP-0117462-A2 | N-(2-4-(1H-imidazol-1-yl)alkyl)arylamides | AMERICAN CYANAMID COMPANY (US) | 1984-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106574-A1 | 2-Arylamino-pyrimidines for the treatment of gsk3-related disorders | GSK3A, GSK3B, CKS2 | SMN1; SMN2 846/4885NPC1 3395/4885POLB 863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.